- About us
- Clinical trials
- News & Publications
SOTIO is developing SOT106 as an ADC against an undisclosed target. SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LegoChem Biosciences industry-leading ConjuAllTM ADC platform technology (learn more here).
SOT106 is currently in preclinical development against solid tumor indications. It shows potential for best-in-class efficacy, safety, and tolerability, leading to a beneficial therapeutic index.